Effect of minocycline about the inhibition of granulomatous inflammation in cardiac sarcoidosis

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461064
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Wakayama Medical University
• Principal Investigator: Orii Makoto 和歌山県立医科大学, 医学部, 助教 (70508986)
• Co-Investigator(Kenkyū-buntansha): Akasaka Takashi 和歌山県立医科大学, 医学部, 教授 (70322584) ; Imanishi Toshio 和歌山県立医科大学, 医学部, 研究員 (00285389) ; Hirata Kumiko 和歌山県立医科大学, 医学部, 講師 (10382152)
• Co-Investigator(Renkei-kenkyūsha): Eishi Yoshinobu 東京医科歯科大学, 医歯(薬)学総合研究科, 教授 (70151959)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 心サルコイドーシス / 炎症性単球 / ミノサイクリン / 肉芽腫 / FDG-PET / 心臓MRI

Outline of Final Research Achievements

We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-FDG PET.
We divided the CS patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+)) and new-onset CS (Rx(－)), and analyzed 3 distinct monocyte subsets (CD14+CD16－, CD14++CD16+, and CD14+－CD16+). Monocyte subsets were also analyzed in Rx(－) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by FDG uptake. The proportion of CD14++CD16+ monocytes in Rx(+) patients was significantly lower than in Rx(－) patients. After corticosteroid therapy, FDG uptake was significantly improved. The proportion of CD14++16+ monocytes showed a significant decrease. The decrease in the proportion of CD14++16+ monocytes significantly correlated with the decrease in FDG uptake.
CD14++16+ monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS.

Free Research Field

非侵襲的画像イメージング